FBRXForte Biosciences, Inc.

Nasdaq fortebiorx.com


$ 0.33 $ 0.03 (10 %)    

Monday, 19-Aug-2024 15:27:50 EDT
QQQ $ 480.76 $ -0.54 (-0.11 %)
DIA $ 409.09 $ 2.37 (0.58 %)
SPY $ 559.11 $ 5.30 (0.96 %)
TLT $ 97.90 $ 0.45 (0.46 %)
GLD $ 231.62 $ -0.38 (-0.16 %)
$ 0.33
$ 0.26 x 600
-- x --
-- - --
$ 0.28 - $ 0.91
251,112
na
12.05M
$ 1.70
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-18-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-31-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-31-2022 12-31-2021 10-K
12 11-08-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 05-10-2021 03-31-2021 10-Q
15 03-16-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 04-23-2020 03-31-2020 10-Q
19 02-27-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 02-27-2019 12-31-2018 10-K
24 11-08-2018 09-30-2018 10-Q
25 08-09-2018 06-30-2018 10-Q
26 05-11-2018 03-31-2018 10-Q
27 03-09-2018 12-31-2017 10-K
28 11-08-2017 09-30-2017 10-Q
29 08-09-2017 06-30-2017 10-Q
30 05-23-2017 03-31-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 chardan-capital-maintains-buy-on-forte-biosciences-maintains-3-price-target

Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and maintains $3 price target.

 forte-biosciences-q2-eps-027-misses-017-estimate

Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $...

 brookline-capital-initiates-coverage-on-forte-biosciences-with-buy-rating-announces-price-target-of-4

Brookline Capital analyst Kumaraguru Raja initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Buy rating and announ...

 ladenburg-thalmann-upgrades-forte-biosciences-to-buy-announces-275-price-target

Ladenburg Thalmann analyst Michael Higgins upgrades Forte Biosciences (NASDAQ:FBRX) from Neutral to Buy and announces $2.75 ...

 forte-biosciences-inc-announces-2023-eps-100-vs-080-yoy

2023 Operating ResultsResearch and development expenses were $21.9 million for the year ended December 31, 2023, compared to $5...

 funicular-funds-in-amended-13d-filing-said--on-oct-28-2023-forte-biosciences-filed-vexatious-legal-action-against-jacob-ma-weaver-and-funicular-funds-believe-allegations-in-the-complaint-are-baseless-and-without-merit

 Funicular Funds has a 5.59% stake in Forte Biosciences

 research-frontiers-and-3-other-stocks-under-1-insiders-are-buying

The Dow Jones index closed higher by over 150 points on Tuesday. When insiders purchase or sell shares, it indicates their conf...

 riskon-international-and-3-other-stocks-under-2-insiders-are-buying

The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence ...

 insiders-buying-vintage-wine-estates-and-3-other-stocks-under-1

The Dow Jones closed higher by over 180 points on Wednesday. When insiders purchase or sell shares, it indicates their confiden...

 forte-biosciences-q3-eps-026-down-from-018-yoy

Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(0.26) per share. This is a 44.44 percent decrease over losses of...

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 647 companies set new 52-week lows.

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 386 stocks made new 52-week lows.

 forte-biosciences-q2-eps-042-down-from-021-yoy

Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(0.42) per share. This is a 100 percent decrease over losses of $...

 stocks-that-hit-52-week-lows-on-friday

  On Friday, 73 companies reached new 52-week lows.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION